Nanocrine real‑time signaling

Cells do not act in still frames, and Nanocrine is building a chip meant to watch their signals move in real time with the National Institutes of Health and the National Cancer Institute. (technical.ly) Cell signaling is the chemical back-and-forth cells use to coordinate growth, stress, immune response, and death. Most lab tests catch one frozen moment, while live-cell imaging follows those signals over time and can reveal behavior that snapshot data misses. (nature.com) (pmc.ncbi.nlm.nih.gov) Nanocrine told Technical.ly it is working with both federal agencies as it develops a platform to observe molecular activity “as it unfolds,” not as a single static image. The company has described that platform as an RT-Chip for plasmonic live-cell imaging on standard lab microscopes. (technical.ly) (nanocrine.com) The company’s recent timeline runs through federal labs and a major cell-biology meeting. Nanocrine said its chip was first tested with living cells at the National Cancer Institute on October 1, 2024, and the company publicly presented the work around the American Society for Cell Biology’s CELL BIO 2025 meeting in Philadelphia on December 6, 2025. (svrglobal.com) (prnewswire.com) What Nanocrine says it wants to measure is not just where a molecule is, but when it appears, how long it stays, and which nearby cells react. That fits a wider research push toward dynamic readouts of signaling networks in living cells, using microscopes and biosensors to track pathways as they switch on and off. (nanocrine.com) (cell.com) (nature.com) Cancer researchers have been moving in the same direction because tumors do not respond to drugs in one uniform way. The National Cancer Institute says its Cellular Cancer Biology Imaging Research centers are developing imaging tools at cellular and organ scales to answer basic cancer-biology questions, and recent reviews describe live-cell imaging as a way to capture treatment response and immune-cell interactions over time. (cancer.gov) (nature.com) Nanocrine has pitched several possible uses: mapping drug response at the cellular level, tracking immune-cell interactions, and identifying biomarkers tied to metastasis or resistance. Those are company claims, not clinical standards, and the current reporting does not show Food and Drug Administration clearance or routine use in cytology labs. (prnewswire.com) (technical.ly) The underlying idea also has limits familiar to anyone working in live-cell imaging. Keeping cells alive on a microscope, separating real signal from noise, and scaling single-cell measurements into clinical workflows are all established technical hurdles, which is why many such tools remain research platforms long before they become diagnostic products. (cshprotocols.cshlp.org) (leica-microsystems.com) For now, the clearest shift is in what scientists are trying to see: not a preserved specimen after the fact, but a cell while it is still making decisions. Nanocrine’s bet is that if researchers can watch those decisions happen, they can test drugs and disease models with more timing, context, and detail than a snapshot allows. (technical.ly) (nature.com)